Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,208.12 +80.43 (+7.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
News headline image
Eli Lilly To Phase Out Select Insulin Products Across Europe By 2027 ↗
Eli Lilly will discontinue select insulin products in EU markets by Q2 2027, citing commercial reasons as regulators monitor supply impact. 
Via Benzinga
News headline image
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer ↗
The company recently obtained approval for a higher-dose version of Wegovy. 
Via The Motley Fool
News headline image
Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark
In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026.... 
Via MarketMinute
Topics ETFs Earnings
News headline image
$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
The Earnings Fortress: S&P 500 Defies 'Permacrisis' with Fifth Consecutive Quarter of Double-Digit Growth
As of March 23, 2026, the American corporate engine has proven itself to be remarkably high-revving, even as the global landscape shifts beneath it. Despite a volatile start to the year characterized... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
What's Going On With Eli Lilly On Monday? ↗
Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court revives Actos litigation risks. 
Via Benzinga
News headline image
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity
As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Here's How Much Upside Eli Lilly Stock Has, According to Analysts ↗
Eli Lilly's stock has been receiving many upgrades after posting strong quarterly results in February. 
Via The Motley Fool
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Buying $1,000 of each of these stocks should pay off nicely over the long run. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have... 
Via StockStory
Topics Artificial Intelligence
News headline image
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
VIG vs NOBL: Which Dividend ETF Should You Buy Now? ↗
Explore how each ETF’s unique sector focus and fee structure could impact your dividend strategy and long-term portfolio mix. 
Via The Motley Fool
Topics ETFs
News headline image
Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗
One of these assets is catalyst-driven; the other isn't. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy Eli Lilly Stock Before April 10? ↗
A catalyst for stock performance may be just ahead. 
Via The Motley Fool
News headline image
Is This Stock a Buy on the Dip? ↗
This company has a habit of beating the market over long periods. 
Via The Motley Fool
News headline image
This Hims & Hers Move Could Destroy Competitors ↗
The Wegovy pill could change Hims & Hers' growth in 2026. 
Via The Motley Fool
News headline image
Buyer’s Remorse: Why the Early-Week Market Rally Collapsed into a Flight for Safety
The promise of a mid-March market recovery vanished this week as a short-lived "relief rally" gave way to a wave of "buyer’s remorse," leaving investors scrambling for cover. What began on Monday as a... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
My Top 3 Drug Stocks for March 2026 ↗
These companies have impressive track records of navigating the biggest challenges in their industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks to Buy Before They Get Bought Out ↗
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets. 
Via The Motley Fool
News headline image
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗
Both have plenty to offer investors, but one has a better outlook. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17% ↗
Eli Lilly says retatrutide trial results show major weight loss and blood sugar improvements in the diabetes study. 
Via Benzinga
News headline image
Is It Too Late to Buy Eli Lilly? ↗
Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy the Vanguard S&P 500 ETF After the Recent Stock Market Sell-Off? History Offers a Crystal-Clear Answer. ↗
Volatility in the stock market often leads to great long-term opportunities for investors. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
1 Reason I'm Never Selling Novo Nordisk Stock ↗
I am not turned off by the company's recent setbacks. 
Via The Motley Fool
News headline image
Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial ↗
Patients taking retatrutide, lost 16.8% of their body weight over 40 weeks. 
Via Investor's Business Daily
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Stock Of The Day: Is The Eli Lilly Selloff Over? ↗
Eli Lilly shares made a large move lower. But they are oversold and getting close to a level where there may be support. 
Via Benzinga
News headline image
Ardsley Dumps 440,000 Hut 8 Shares Worth $19.4 Million ↗
Hut 8 operates large-scale data centers supporting Bitcoin mining and high-performance computing for institutional clients. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year... 
Via Finterra
Topics Intellectual Property
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.